ESR1 and breast carcinoma: The American Society of Clinical Oncology (ASCO) Guideline 2020 for Estrogen and Progesterone Receptor Testing in Breast Cancer strongly suggests that low positivity of ER expression (1–10%) is associated with limited data on endocrine therapy benefits [46].